BioSpace News Archive

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced the closing of its previously announced public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company

Visage Imaging, Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced Visage will be exhibiting under the theme of “Platform for the Future—Powered by Speed,” highlighted by the demonstration of the Visage® 7 Enterprise Imaging Platform, at the Radiological Society of North America (RSNA) 2019 annual meeting (Visage Booth 7524, McCormick Place-North Hall

Technavio has been monitoring the global aneurysm coiling and embolization devices market and the market is poised to grow by USD 1.61 billion during 2019-2023 at a CAGR of over 10% during the forecast period.

Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) will release its 2019 third quarter financial results on Thursday, November 21, 2019, prior to the market open and management will host a conference call at 10:00 AM Eastern Time to review the financial results.

HYLETE, Inc. today announced that it has postponed its previously announced initial public offering.

The U.S. Food and Drug Administration today cleared for marketing in the U.S. the first duodenoscope with a sterile, disposable elevator component that will reduce the number of parts that need to be cleaned and disinfected (reprocessed) in between uses.

Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older.

BD announced that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation to purchase up to 500,000 shares of BDX common stock at a price of $234.00 per share in cash.

Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the Jefferies 2019 Global Healthcare Conference in London, United Kingdom on Wednesday, November 20, 2019 at 6:00 p.m. GMT.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company.